Reaction: SLC27A2 ligates CoA to bempedoic acid to form ETC-1002-CoA
- in pathway: Fatty acyl-CoA biosynthesis
Bempedoic acid (ETC-1002) is first-in-class ATP-citrate lyase (ACLY) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. ETC-1002 itself is a prodrug, which is converted to the active metabolite ETC-1002–CoA by endogenous liver acyl-CoA synthetase (SLC27A2, ACSVL1) activity (Pinkosky et al. 2016).
Reaction - small molecule participants:
PPi [cytosol]
AMP [cytosol]
ATP [cytosol]
CoA-SH [cytosol]
Reactome.org reaction link: R-HSA-9734535
======
Reaction input - small molecules:
ATP(4-)
coenzyme A(4-)
Reaction output - small molecules:
diphosphate(3-)
adenosine 5'-monophosphate(2-)
Reactome.org link: R-HSA-9734535